292:. It was one of the first companies formed to utilize the CRISPR gene editing platform to develop medicines for the treatment of various rare and common diseases. The company has approximately 500 employees and has offices in Zug, Switzerland, Boston, Massachusetts, San Francisco, California and London, United Kingdom. Its manufacturing facility in Framingham, Massachusetts won the Facilities of the Year Award (FOYA) award in 2022. The company’s lead program,
320:. This allows DNA to be specifically modified and edited, which can be used to ameliorate diseases. CRISPR Therapeutics is applying this technology platform to research, develop and commercialize medicines for various diseases including sickle cell disease, beta thalassemia, various cancers, type 1 diabetes, and cardiovascular diseases. The CEO is Samarth Kulkarni, PhD, who joined the company in 2015 as chief business officer. Kulkarni became CEO in 2017.
29:
205:
186:
240:
223:
167:
378:(BLAs) were submitted to the FDA for exa-cel for sickle cell disease and transfusion-dependent beta thalassemia. EU and UK filings were completed in 2022, and the submissions were validated by European Medicines Agency and The Medicines and Healthcare products Regulatory Agency as of April 2023.
323:
CRISPR Therapeutics has formed collaborations in support of its mission of developing medicines. Vertex
Pharmaceuticals and CRISPR Therapeutics entered into a strategic research collaboration in 2015 focused on the use of CRISPR/Cas9 to discover and develop potential new treatments aimed at the
324:
underlying genetic causes of human disease. One of the first treatments to emerge from the joint research program was CTX001 or exagamglogene autotemcel (commonly known as Exa-cel). Subsequently, CRISPR Therapeutics and Vertex expanded their collaboration to include diseases like
735:
Frangoul, Haydar; Altshuler, David; Cappellini, M. Domenica; Chen, Yi-Shan; Domm, Jennifer; Eustace, Brenda K.; Foell, Juergen; de la Fuente, Josu; Grupp, Stephan; Handgretinger, Rupert; Ho, Tony W. (21 January 2021).
705:
CRISPR Therapeutics and Vertex
Pharmaceuticals Announce FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to CTX001™ for the Treatment of Severe Hemoglobinopathies
447:
912:
374:
for sickle cell disease and transfusion-dependent beta thalassemia. As of 2022 Phase 3 clinical trial results supported the safety and efficacy of this treatment. The rolling
332:
to operate
Casebia Therapeutics as a joint venture with Bayer under the management of CRISPR Therapeutics. The company went public on the NASDAQ exchange in October 2016.
572:
818:
897:
72:
892:
669:
704:
590:
917:
651:
335:
CRISPR Therapeutics has established partnerships with additional companies such as
Viacyte (part of Vertex), Nkarta, Capsida, Curevac, and others.
887:
415:
429:
922:
608:
717:
528:
177:
486:
554:
902:
411:
296:, or exa-cel (formerly CTX001), was granted regulatory approval by the US Food and Drug Administration (FDA) in December 2023.
687:
343:
CRISPR Therapeutics has drugs approved and in development for blood diseases, cancer, diabetes, and other severe diseases.
375:
907:
325:
370:
designation from the US Food and Drug
Administration (FDA) for transfusion-dependent beta thalassemia and from the
633:
371:
309:
293:
316:. As part of a working group, she provided the first scientific documentation on the development and use of
153:
363:
305:
120:
392:
359:
317:
366:, that received FDA approval for clinical use in December 2023. In May 2020, exa-cel had received
775:
465:
864:
767:
759:
573:"Vertex Dives into DMD with Exonics Acquisition and CRISPR Therapeutics Partnership Expansion"
856:
749:
355:
232:
387:
313:
28:
47:
505:
881:
844:
779:
89:
65:
55:
670:"CRISPR Therapeutics inks deal with Nkarta on gene-edited cell therapies for cancer"
793:
652:"CRISPR and Capsida Partner in Gene Edited Therapies for ALS, Friedreich's Ataxia"
448:"A Young Mississippi Woman's Journey Through A Pioneering Gene-Editing Experiment"
78:
367:
289:
860:
196:
763:
591:"Vertex doubles down on CRISPR Therapeutics and diabetes in new $ 100M deal"
868:
771:
430:"CRISPR Therapeutics, Vertex Start First Company-Backed Human CRISPR Trial"
754:
737:
510:
329:
487:"F.D.A. Approves Sickle Cell Treatments, Including One That Uses CRISPR"
609:"Bayer backs off running Casebia JV as CRISPR Tx takes over management"
351:
819:"1st Patients To Get CRISPR Gene-Editing Treatment Continue To Thrive"
718:"Vertex, CRISPR strengthen case for pioneering gene-editing treatment"
61:
738:"CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia"
328:
and type 1 diabetes. In 2016, the company signed an agreement with
215:
634:"Crispr's Nobel prize and IPOs both happened at lightning speed"
354:
is a drug therapy for the treatment of the rare blood disorders
285:
139:
308:, Shaun Foy and Rodger Novak. Charpentier later shared the
284:
is a Swiss–American biotechnology company headquartered in
529:"CRISPR Therapeutics: Ist diese Aktie nobelpreiswĂĽrdig?"
688:"CRISPR, Bayer JV tap CureVac for Cas9 mRNA constructs"
262:
257:
247:
230:
213:
194:
175:
160:
146:
135:
113:
95:
85:
71:
53:
43:
35:
506:"Disease is in the sights of gene reprogrammers"
481:
479:
845:"First CRISPR therapy seeks landmark approval"
707:, PM Vertex 11 May 2020; retrieved 11 May 2020
555:"CRISPR Partnerships Seek Win-Win Situations"
8:
559:Genetic Engineering & Biotechnology News
21:
913:Biotechnology companies established in 2013
412:"CRISPR Therapeutics AG 2023 Annual Report"
304:CRISPR Therapeutics was founded in 2013 by
794:"Synthego | Full Stack Genome Engineering"
20:
753:
204:
185:
416:U.S. Securities and Exchange Commission
403:
898:Biotechnology companies of Switzerland
466:"2022 Category Winner for Innovation"
7:
523:
521:
16:Swiss-American biotechnology company
893:Swiss companies established in 2013
918:2013 establishments in Switzerland
208:US$ −154 million (2023)
189:US$ −223 million (2023)
14:
843:Kingwell, Katie (3 April 2023).
239:
238:
222:
221:
203:
184:
166:
165:
27:
742:New England Journal of Medicine
273:Footnotes / references
888:Companies listed on the Nasdaq
376:Biologics License Applications
1:
923:2016 initial public offerings
849:Nature Reviews Drug Discovery
243:US$ 1.88 billion (2023)
226:US$ 2.23 billion (2023)
504:Arney, Kat (22 June 2016).
326:Duchenne muscular dystrophy
170:US$ 371 million (2023)
101:; 11 years ago
939:
861:10.1038/d41573-023-00050-8
372:European Medicines Agency
271:
26:
310:Nobel Prize in Chemistry
294:exagamglogene autotemcel
362:developed jointly with
903:Companies based in Zug
364:Vertex Pharmaceuticals
306:Emmanuelle Charpentier
282:CRISPR Therapeutics AG
121:Emmanuelle Charpentier
22:CRISPR Therapeutics AG
755:10.1056/NEJMoa2031054
393:Intellia Therapeutics
694:. 13 November 2017.
454:. 25 December 2019.
418:. 21 February 2024.
360:sickle cell disease
318:CRISPR gene editing
249:Number of employees
23:
908:Genomics companies
493:. 8 December 2023.
152:Samarth Kulkarni (
39:Inception Genomics
674:The Pharma Letter
640:. 7 October 2020.
436:. 31 August 2018.
279:
278:
930:
873:
872:
840:
834:
833:
831:
829:
815:
809:
808:
806:
804:
798:www.synthego.com
790:
784:
783:
757:
732:
726:
725:
714:
708:
702:
696:
695:
684:
678:
677:
666:
660:
659:
648:
642:
641:
630:
624:
623:
621:
619:
605:
599:
598:
597:. 27 March 2023.
587:
581:
580:
569:
563:
562:
551:
545:
544:
542:
540:
525:
516:
515:
501:
495:
494:
483:
474:
473:
462:
456:
455:
444:
438:
437:
426:
420:
419:
408:
356:beta thalassemia
267:
264:
242:
241:
235:
225:
224:
218:
209:
207:
206:
190:
188:
187:
178:Operating income
171:
169:
168:
109:
107:
102:
81:
31:
24:
938:
937:
933:
932:
931:
929:
928:
927:
878:
877:
876:
842:
841:
837:
827:
825:
817:
816:
812:
802:
800:
792:
791:
787:
734:
733:
729:
724:. 11 June 2022.
716:
715:
711:
703:
699:
686:
685:
681:
668:
667:
663:
658:. 15 June 2021.
650:
649:
645:
632:
631:
627:
617:
615:
607:
606:
602:
589:
588:
584:
571:
570:
566:
561:. 3 March 2022.
553:
552:
548:
538:
536:
527:
526:
519:
503:
502:
498:
485:
484:
477:
464:
463:
459:
446:
445:
441:
428:
427:
423:
410:
409:
405:
401:
388:Editas Medicine
384:
349:
341:
314:Jennifer Doudna
302:
275:
261:
250:
231:
214:
202:
199:
183:
180:
164:
149:
131:
105:
103:
100:
77:
58:
17:
12:
11:
5:
936:
934:
926:
925:
920:
915:
910:
905:
900:
895:
890:
880:
879:
875:
874:
855:(5): 339–341.
835:
810:
785:
748:(3): 252–260.
727:
722:Biopharma Dive
709:
697:
692:Fierce Biotech
679:
676:. 5 July 2021.
661:
643:
625:
600:
595:Fierce Biotech
582:
579:. 7 June 2019.
564:
546:
517:
496:
491:New York Times
475:
457:
439:
421:
402:
400:
397:
396:
395:
390:
383:
380:
348:
345:
340:
337:
301:
298:
277:
276:
269:
268:
259:
255:
254:
251:
248:
245:
244:
236:
228:
227:
219:
211:
210:
200:
195:
192:
191:
181:
176:
173:
172:
162:
158:
157:
150:
147:
144:
143:
137:
133:
132:
130:
129:
126:
123:
117:
115:
111:
110:
97:
93:
92:
87:
83:
82:
75:
69:
68:
59:
54:
51:
50:
45:
41:
40:
37:
33:
32:
15:
13:
10:
9:
6:
4:
3:
2:
935:
924:
921:
919:
916:
914:
911:
909:
906:
904:
901:
899:
896:
894:
891:
889:
886:
885:
883:
870:
866:
862:
858:
854:
850:
846:
839:
836:
824:
820:
814:
811:
799:
795:
789:
786:
781:
777:
773:
769:
765:
761:
756:
751:
747:
743:
739:
731:
728:
723:
719:
713:
710:
706:
701:
698:
693:
689:
683:
680:
675:
671:
665:
662:
657:
653:
647:
644:
639:
635:
629:
626:
614:
613:FierceBiotech
610:
604:
601:
596:
592:
586:
583:
578:
574:
568:
565:
560:
556:
550:
547:
534:
533:GodmodeTrader
530:
524:
522:
518:
513:
512:
507:
500:
497:
492:
488:
482:
480:
476:
471:
467:
461:
458:
453:
449:
443:
440:
435:
434:FierceBiotech
431:
425:
422:
417:
413:
407:
404:
398:
394:
391:
389:
386:
385:
381:
379:
377:
373:
369:
365:
361:
357:
353:
346:
344:
338:
336:
333:
331:
327:
321:
319:
315:
312:in 2020 with
311:
307:
299:
297:
295:
291:
287:
283:
274:
270:
266:
260:
256:
252:
246:
237:
234:
229:
220:
217:
212:
201:
198:
193:
182:
179:
174:
163:
159:
155:
151:
145:
142:, Switzerland
141:
138:
134:
127:
124:
122:
119:
118:
116:
112:
98:
94:
91:
90:Biotechnology
88:
84:
80:
76:
74:
70:
67:
63:
60:
57:
52:
49:
46:
42:
38:
34:
30:
25:
19:
852:
848:
838:
826:. Retrieved
822:
813:
801:. Retrieved
797:
788:
745:
741:
730:
721:
712:
700:
691:
682:
673:
664:
655:
646:
637:
628:
616:. Retrieved
612:
603:
594:
585:
576:
567:
558:
549:
537:. Retrieved
532:
509:
499:
490:
469:
460:
451:
442:
433:
424:
406:
350:
342:
334:
322:
303:
281:
280:
272:
233:Total equity
216:Total assets
136:Headquarters
128:Rodger Novak
79:CH0334081137
44:Company type
18:
828:21 February
803:21 February
535:(in German)
368:orphan drug
290:Switzerland
882:Categories
399:References
253:407 (2023)
197:Net income
148:Key people
780:227521558
764:0028-4793
618:8 January
539:8 January
125:Shaun Foy
56:Traded as
869:37012339
772:33283989
656:BioSpace
577:Biospace
511:Wired UK
382:See also
339:Products
330:Bayer AG
263:crisprtx
114:Founders
86:Industry
36:Formerly
823:NPR.org
472:. 2022.
352:Exa-cel
347:Exa-cel
300:History
258:Website
161:Revenue
104: (
96:Founded
64::
867:
778:
770:
762:
638:Quartz
62:Nasdaq
48:Public
776:S2CID
865:PMID
830:2021
805:2021
768:PMID
760:ISSN
620:2021
541:2021
470:ISPE
358:and
265:.com
106:2013
99:2013
73:ISIN
66:CRSP
857:doi
750:doi
746:384
452:NPR
286:Zug
154:CEO
140:Zug
884::
863:.
853:22
851:.
847:.
821:.
796:.
774:.
766:.
758:.
744:.
740:.
720:.
690:.
672:.
654:.
636:.
611:.
593:.
575:.
557:.
531:.
520:^
508:.
489:.
478:^
468:.
450:.
432:.
414:.
288:,
871:.
859::
832:.
807:.
782:.
752::
622:.
543:.
514:.
156:)
108:)
Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.
